D Walsh-McMonagle1, D Green. 1. Department of Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago and Northwestern University Medical School, Illinois 60611, USA.
Abstract
BACKGROUND: Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin. METHODS: Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed. RESULTS: All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy. CONCLUSIONS: Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder.
BACKGROUND:Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin. METHODS: Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed. RESULTS: All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy. CONCLUSIONS: Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder.
Authors: Elenir B C Avritscher; Scott B Cantor; Ya-Chen T Shih; Carmelita P Escalante; Edgardo Rivera; Linda S Elting Journal: Support Care Cancer Date: 2004-02-21 Impact factor: 3.603
Authors: Jeong Won Jang; Chang Dong Yeo; Jin Dong Kim; Si Hyun Bae; Jong Young Choi; Eun Sun Jung; Sung Eun Rha; Jae Young Byun; Seung Kew Yoon Journal: J Korean Med Sci Date: 2006-02 Impact factor: 2.153